UTI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
UTI is not a good buy right now for an impatient buyer. Price action is sitting near the pivot (~28.08) with weakening momentum (bearish MACD expansion) and no Intellectia entry signals, while hedge funds are actively reducing exposure. Despite bullish insider buying and constructive long-term odds over the next month, the near-term setup isn’t strong enough to justify an immediate chase at ~28.4 ahead of earnings.
Trend/Momentum: Mixed-to-slightly bearish near-term. MACD histogram is below zero (-0.00432) and negatively expanding, signaling fading upside momentum. RSI(6) at ~51 is neutral (no immediate oversold bounce signal). Moving averages are converging, consistent with consolidation rather than a clean trend.
Key levels: Pivot 28.079 is the main battleground. Immediate resistance is R1 29.233 (then R2 29.946). Support is S1 26.926 (then S2 26.213). Post-market strength (28.38, +1.98%) helps, but the regular session was down (-0.75%), so follow-through needs confirmation above ~29.23.
Pattern-based forward odds (given): ~60% chance of modest gains over the next month (+4.63%), but next-day/next-week edges are small.
Intellectia Proprietary Trading Signals
Business expansion/news flow around Concorde Career Colleges (UTI’s education platform) including community events and plans to open a new Phoenix healthcare facility in 2027—supports longer-term growth narrative and demand-driven training.
Insider activity: insiders are buying heavily (buying amount up ~5287% over the last month), a bullish alignment signal.
Earnings catalyst ahead: QDEC 2025 earnings on 2026-02-04 after hours (consensus EPS est. ~0.15). Elevated IV suggests the market expects a notable move.
Fund flows: Hedge funds are selling, with selling amount up ~295.7% over the last quarter—near-term institutional pressure.
Technical momentum is not confirming upside yet (MACD bearish expansion, MAs converging), increasing the chance of chop between ~26.9–29.
High implied volatility indicates the market is demanding a premium for uncertainty into earnings, often coinciding with sharp swings.
Latest quarter: 2025/Q4. Revenue grew to $222.44M (+13.28% YoY), showing solid top-line momentum. EPS rose to $0.34 (+3.03% YoY) and gross margin improved slightly to ~49.53 (+0.26 YoY), indicating stable-to-improving unit economics. Net income was essentially flat/slightly down ($18.76M, -0.45% YoY), suggesting profitability growth is lagging revenue growth but not deteriorating meaningfully.
No analyst rating/price target change data was provided, so a verified recent trend can’t be summarized from the dataset. Wall Street-style pro view (based on fundamentals here): consistent revenue growth and stable margins. Con view: profit growth is modest vs revenue growth and current tape shows institutional selling pressure (hedge fund selling). Politician/congress trading: no recent congress trading data available.
